Combined medicine for preventing and treating tumors

A drug and tumor technology, applied in the field of medicine, can solve the problems of chemotherapeutic drug resistance, lower drug efficacy, and unclear right and wrong, and achieve the effects of expanding the applicable population, improving curative effect, and less toxic and side effects

Inactive Publication Date: 2014-05-21
SHENYANG PHARMA UNIVERSITY
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although chemotherapy has played a greater role in curing the disease, increasing the surgical resection rate and survival rate, and improving the quality of life, its problems cannot be ignored.
Most chemotherapeutic drugs lack ideal selectivity, leading to "discernment between right and wrong" and "no distinction between the enemy and the enemy". While killing tumor cells, they also kill normal cells of the human body (such as inhibition of bone marrow hematopoietic system, liver cell damage, irreversible and Accumulative cardiotoxicity, etc.), resulting in varying degrees of damage to the patient's body function and making it unbearable for the patient, forcing the interruption of the normal course of treatment, which greatly reduces the efficacy of the drug; Application has certain limitations

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0027] Example 1: Study on anti-S180 tumor effect of cucurbitacin B (CuB) and coenzyme Q10 (Q10)

[0028] Experimental program:

[0029] Take Kunming mice, weighing 18-22 grams, male, inoculate S180 tumor in the armpit of the right forelimb, and wait until the tumor mass grows to be larger than 50 mm 2 At the time, they were randomly divided into 3 groups, each with 10 animals, and each group was given intragastric administration separately. The scheme is as follows:

[0030] Dosage: CuB: B( 5 mg / kg)

[0031] Q10: Q (50 mg / kg)

[0032] Mode of administration: CuB emulsion, B+Q composite emulsion

[0033] Control group: normal saline group

[0034] Experimental group: CuB group, CuB+Q10 group

[0035] The administration was continued for 14 days. Within 24 hours after the last administration, the animals were sacrificed and the tumors were weighed to calculate the tumor inhibition rate.

[0036] Results: The tumor inhibition rates of CuB group and CuB+Q10 group were 48.

Example Embodiment

[0038] Example 2: Study on anti-S180 tumor effect of cucurbitacin B (CuB) and taurine (T)

[0039] Experimental program:

[0040] Take Kunming mice, weighing 18-22 grams, male, inoculate S180 tumor under the armpit of the right forelimb, and wait until the tumor mass grows to more than 50 mm 2 At the time, they were randomly divided into 3 groups, 10 animals in each group, and each group was given intragastric administration separately. The scheme is as follows:

[0041] Dosage: CuB: 5 mg / kg

[0042] T: 300 mg / kg

[0043] Administration method: CuB emulsion, CuB+T composite emulsion

[0044] Control group: normal saline group

[0045] Experimental group: CuB emulsion group, CuB+T composite emulsion group

[0046] The administration was continued for 14 days. Within 24 hours after the last administration, the animals were sacrificed and the tumors were weighed to calculate the tumor inhibition rate.

[0047] Results: The tumor inhibition rates of CuB emulsion g

Example Embodiment

[0049] Example 3: Study on anti-H22 tumor effect of cucurbitacin B (CuB) and coenzyme Q10 (Q10)

[0050] Experimental program:

[0051] Take Kunming mice, weighing 18-22 grams, male, inoculate H22 tumor in the armpit of the right forelimb, and wait until the tumor mass grows to be larger than 50 mm 2 At the time, they were randomly divided into 3 groups, 10 animals in each group, and each group was given intragastric administration separately. The scheme is as follows:

[0052] Dosage: CuB: B( 5 mg / kg)

[0053] Q10: Q (50 mg / kg)

[0054] Mode of administration: CuB emulsion, B+Q composite emulsion

[0055] Control group: normal saline group

[0056] Experimental group: CuB group, CuB+Q10 group

[0057] The administration was continued for 14 days. Within 24 hours after the last administration, the animals were sacrificed and the tumors were weighed to calculate the tumor inhibition rate.

[0058] Results: The tumor inhibition rates of CuB group and CuB+Q10 group w

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a combined medicine for preventing and treating tumors, which has the effects of reducing side effects of chemotherapy and radiotherapy. The combined medicine for preventing and treating tumors comprises cucurbitacine and at least one of coenzyme Q10 and taurine, wherein the weight ratio of cucurbitacine to coenzyme Q10 is 1:(0.1-10000); the weight ratio of cucurbitacine to taurine is 1:(0.1-10000). When the medicine is formed by cucurbitacine, coenzyme Q10 and taurine, the weight ratio of cucurbitacine to coenzyme Q10 to taurine is 1:(0.1-10000):(0.1-10000). The dosage is also provided. The combined medicine can be processed into tablets, capsules, granules, powder, patches, ointment, suspension, syrup, sustained-release preparations, nano-particles or emulsion and other preparations with pharmaceutically acceptable carriers commonly or respectively. The combined medicine can be used in chronic hepatitis treatment and prevention and treatment of cancers in clinical application.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products